Sex Chromosome Disorders News - LARVOL Sigma

Sex Chromosome Disorders

Welcome, Profile Billing Logout

0 Mechanisms of Action

|||||||||| Trial completion: Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure (clinicaltrials.gov) - Nov 17, 2014
P=N/A, N=72, Completed, Sponsor: National Eye Institute (NEI)
Recruiting --> Completed

||||||||||  Nebido (testosterone undecanoate depot injection) / Bayer
Trial completion, Enrollment change:  ALCeP: Androgen for Leydig Cell Proliferation (clinicaltrials.gov) -  Oct 28, 2014
P2/3, N=56, Completed,  Sponsor: University of Roma La Sapienza
Recruiting --> Completed Recruiting --> Completed | N=20 --> 56

|||||||||| Clinical: Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies (clinicaltrials.gov) - Aug 27, 2014
P=N/A, N=1000, Recruiting, Sponsor: Sequenom, Inc.

||||||||||  basimglurant (NOE-101) / Noema Pharma
Trial completion:  A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome (clinicaltrials.gov) -  Aug 27, 2014
P2, N=47, Completed,  Sponsor: Hoffmann-La Roche
Recruiting --> Completed | N=20 --> 56 Active, not recruiting --> Completed

||||||||||  Zomacton (somatropin) / Ferring
Enrollment open, Adherence:  ZOMAXEPT: Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device (clinicaltrials.gov) -  Jul 17, 2014
P=N/A, N=90, Recruiting,  Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  metadoxine extended-release (MG01CI) / Arcturus Therap
Enrollment open:  A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome (clinicaltrials.gov) -  Jul 12, 2014
P2, N=60, Recruiting,  Sponsor: Alcobra Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting

|||||||||| Trial completion: Turner Syndrome: Genotype and Phenotype (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=1017, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed

|||||||||| Trial termination: DHEAFert: Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility (clinicaltrials.gov) - Jul 1, 2014
P2/3, N=35, Terminated, Sponsor: Center for Human Reproduction
Active, not recruiting --> Completed Recruiting --> Terminated; Failure to recruit designed nuimebrt of subjects

|||||||||| Enrollment change, Trial termination: DHEAFert: Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility (clinicaltrials.gov) - Jul 1, 2014
P2/3, N=35, Terminated, Sponsor: Center for Human Reproduction
Recruiting --> Terminated; Failure to recruit designed nuimebrt of subjects N=220 --> 35 | Recruiting --> Terminated; Failure to recruit designed nuimebrt of subjects

|||||||||| Enrollment open: Prenatal Screening for Down Syndrome With DNAFirst (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=100, Recruiting, Sponsor: Women and Infants Hospital of Rhode Island
N=220 --> 35 | Recruiting --> Terminated; Failure to recruit designed nuimebrt of subjects Not yet recruiting --> Recruiting

|||||||||| Enrollment open, Trial initiation date: Prenatal Screening for Down Syndrome With DNAFirst (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=100, Not yet recruiting, Sponsor: Women and Infants Hospital of Rhode Island
Not yet recruiting --> Recruiting Initiation date: Nov 2013 --> Mar 2014 | Not yet recruiting --> Recruiting

|||||||||| Clinical: Risk of Diabetes in Young Turner Syndrome Patients (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=120, Recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati

||||||||||  mavoglurant (AFQ056) / Novartis
Trial primary completion date:  Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) (clinicaltrials.gov) -  May 20, 2014
P2/3, N=170, Recruiting,  Sponsor: Novartis Pharmaceuticals
Initiation date: Nov 2013 --> Mar 2014 | Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Aug 2014

||||||||||  mavoglurant (AFQ056) / Novartis
Trial completion date:  Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) (clinicaltrials.gov) -  May 20, 2014
P2/3, N=170, Recruiting,  Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Aug 2014 Trial completion date: Dec 2015 --> Aug 2014

||||||||||  mavoglurant (AFQ056) / Novartis
Trial primary completion date:  Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome (clinicaltrials.gov) -  May 20, 2014
P2, N=200, Recruiting,  Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2015 --> Aug 2014 Trial primary completion date: Dec 2015 --> Aug 2014

||||||||||  mavoglurant (AFQ056) / Novartis
Trial completion date:  Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome (clinicaltrials.gov) -  May 20, 2014
P2, N=200, Recruiting,  Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Aug 2014 Trial completion date: Dec 2015 --> Aug 2014

||||||||||  metadoxine extended-release (MG01CI) / Arcturus Therap
Trial primary completion date:  A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome (clinicaltrials.gov) -  May 17, 2014
P2, N=60, Not yet recruiting,  Sponsor: Alcobra Ltd.
Trial completion date: Dec 2015 --> Aug 2014 Trial primary completion date: Jan 2015 --> Dec 2014

|||||||||| Trial primary completion date: Klinefelter Fertility Preservation (clinicaltrials.gov) - May 13, 2014
P=N/A, N=15, Completed, Sponsor: Children's Hospital Boston
Trial primary completion date: Jan 2015 --> Dec 2014 Trial primary completion date: Oct 2013 --> Apr 2014

|||||||||| Enrollment change: Klinefelter Fertility Preservation (clinicaltrials.gov) - May 13, 2014
P=N/A, N=15, Completed, Sponsor: Children's Hospital Boston
Trial primary completion date: Oct 2013 --> Apr 2014 N=20 --> 15

|||||||||| Trial completion: Klinefelter Fertility Preservation (clinicaltrials.gov) - May 13, 2014
P=N/A, N=15, Completed, Sponsor: Children's Hospital Boston
N=20 --> 15 Recruiting --> Completed

||||||||||  mavoglurant (AFQ056) / Novartis
Trial completion:  Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome (clinicaltrials.gov) -  May 11, 2014
P2, N=139, Completed,  Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed

||||||||||  basimglurant (NOE-101) / Noema Pharma
Trial completion:  A Study of RO4917523 in Patients With Fragile X Syndrome (clinicaltrials.gov) -  May 11, 2014
P2, N=185, Completed,  Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial primary completion date: Sex Differences in Early Brain Development; Brain Development in Turner Syndrome (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=295, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Trial primary completion date: May 2013 --> May 2014

|||||||||| Trial completion date: Sex Differences in Early Brain Development; Brain Development in Turner Syndrome (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=295, Completed, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: May 2013 --> May 2014 Trial completion date: May 2013 --> May 2014

|||||||||| Trial completion: Sex Differences in Early Brain Development; Brain Development in Turner Syndrome (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=295, Completed, Sponsor: University of North Carolina, Chapel Hill
Trial completion date: May 2013 --> May 2014 Active, not recruiting --> Completed

||||||||||  metadoxine extended-release (MG01CI) / Arcturus Therap
New P2 trial:  A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome (clinicaltrials.gov) -  Apr 28, 2014
P2, N=60, Not yet recruiting,  Sponsor: Alcobra Ltd.

||||||||||  donepezil / Generic mfg.
Trial completion:  Randomized Controlled Study of Donepezil in Fragile X Syndrome (clinicaltrials.gov) -  Apr 6, 2014
P2, N=45, Completed,  Sponsor: Stanford University
Active, not recruiting --> Completed Recruiting --> Completed

||||||||||  Zomacton (somatropin) / Ferring
Trial initiation date, Adherence:  ZOMAXEPT: Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device (clinicaltrials.gov) -  Mar 23, 2014
P=N/A, N=90, Not yet recruiting,  Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed Initiation date: Mar 2014 --> Jun 2014

|||||||||| Enrollment open: Genetic Etiology in Premature Ovarian Insufficiency (clinicaltrials.gov) - Mar 17, 2014
P=N/A, N=100, Recruiting, Sponsor: BEGUM AYDOGAN
Initiation date: Mar 2014 --> Jun 2014 Not yet recruiting --> Recruiting

|||||||||| Trial completion: Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome (clinicaltrials.gov) - Feb 19, 2014
P2, N=80, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting --> Recruiting No longer recruiting --> Completed

||||||||||  somatropin / Generic mfg.
Enrollment closed:  GeNeSIS: Observational Study of Somatropin Treatment in Children (clinicaltrials.gov) -  Feb 16, 2014
P=N/A, N=23500, Active, not recruiting,  Sponsor: Eli Lilly and Company
No longer recruiting --> Completed Enrolling by invitation --> Active, not recruiting

||||||||||  Zorbtive (somatropin) / EMD Serono
Biomarker, Trial completion:  PREDICT LT FUP: Long Term Follow up Study of Predictive Markers in GHD and TS Children (clinicaltrials.gov) -  Feb 16, 2014
P=N/A, N=182, Completed,  Sponsor: Merck KGaA
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  trofinetide (NNZ-2566) / Neuren, Acadia Pharma
Enrollment open:  A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome (clinicaltrials.gov) -  Feb 3, 2014
P2, N=60, Recruiting,  Sponsor: Neuren Pharmaceuticals Limited
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  basimglurant (NOE-101) / Noema Pharma
Enrollment closed:  A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome (clinicaltrials.gov) -  Jan 19, 2014
P2, N=47, Active, not recruiting,  Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting

||||||||||  trofinetide (NNZ-2566) / Neuren, Acadia Pharma
Trial initiation date:  A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome (clinicaltrials.gov) -  Jan 18, 2014
P2, N=60, Recruiting,  Sponsor: Neuren Pharmaceuticals Limited
Recruiting --> Active, not recruiting Initiation date: Oct 2013 --> Jan 2014

||||||||||  basimglurant (NOE-101) / Noema Pharma
Enrollment closed:  A Study of RO4917523 in Patients With Fragile X Syndrome (clinicaltrials.gov) -  Jan 12, 2014
P2, N=185, Active, not recruiting,  Sponsor: Hoffmann-La Roche
Initiation date: Oct 2013 --> Jan 2014 Recruiting --> Active, not recruiting

||||||||||  Zomacton (somatropin) / Ferring
Adherence:  ZOMAXEPT: Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device (clinicaltrials.gov) -  Dec 19, 2013
P=N/A, N=90, Not yet recruiting,  Sponsor: Ferring Pharmaceuticals

||||||||||  Vivelle (estradiol transdermal system) / Sanofi, Hisamitsu, Novartis, Estreva oral (estradiol oral) / EMD Serono, Estrace (estradiol) / AbbVie
Trial completion:  Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism (clinicaltrials.gov) -  Dec 18, 2013
P4, N=41, Completed,  Sponsor: Nemours Children's Clinic
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Biomarker, Trial completion: EMR 200104_010: First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study (clinicaltrials.gov) - Nov 25, 2013
P4, N=458, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Enrollment closed: GenTAC: National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (clinicaltrials.gov) - Nov 13, 2013
P=N/A, N=3800, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

|||||||||| Enrollment change: Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure (clinicaltrials.gov) - Oct 15, 2013
P=N/A, N=71, Recruiting, Sponsor: National Eye Institute (NEI)
Recruiting --> Active, not recruiting N=53 --> 71

|||||||||| Enrollment open: Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure (clinicaltrials.gov) - Oct 15, 2013
P=N/A, N=71, Recruiting, Sponsor: National Eye Institute (NEI)
N=53 --> 71 Completed --> Recruiting

||||||||||  arbaclofen (STX209) / Allos Pharma
Trial termination:  An Open Label Extension Study in Subjects With Fragile X Syndrome (clinicaltrials.gov) -  Jul 29, 2013
P3, N=357, Terminated,  Sponsor: Seaside Therapeutics, Inc.
Completed --> Recruiting Enrolling by invitation --> Terminated

||||||||||  arbaclofen (STX209) / Allos Pharma
Trial completion:  Harbor-C: Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome (clinicaltrials.gov) -  Jul 29, 2013
P3, N=172, Completed,  Sponsor: Seaside Therapeutics, Inc.
Enrolling by invitation --> Terminated Active, not recruiting --> Completed

||||||||||  arbaclofen (STX209) / Allos Pharma
Trial completion:  Harbor-A: Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome (clinicaltrials.gov) -  Jul 29, 2013
P3, N=125, Completed,  Sponsor: Seaside Therapeutics, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  arbaclofen (STX209) / Allos Pharma
Biomarker, Trial completion:  Biomarker and DNA Collection in Subjects Participating in Protocol 22003 (clinicaltrials.gov) -  Jul 29, 2013
P=N/A, N=32, Completed,  Sponsor: Seaside Therapeutics, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  arbaclofen (STX209) / Allos Pharma
Biomarker, Trial completion:  Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001 (clinicaltrials.gov) -  Jul 29, 2013
P=N/A, N=0, Completed,  Sponsor: Seaside Therapeutics, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: Comparison of Aneuploidy Risk Evaluations (clinicaltrials.gov) - Jul 11, 2013
P=N/A, N=3000, Completed, Sponsor: Verinata Health, Inc.
Active, not recruiting --> Completed Recruiting --> Completed

||||||||||  trofinetide (NNZ-2566) / Neuren, Acadia Pharma
New P2 trial:  A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome (clinicaltrials.gov) -  Jul 8, 2013
P2, N=60, Recruiting,  Sponsor: Neuren Pharmaceuticals Limited

|||||||||| Enrollment change: Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome (clinicaltrials.gov) - Jun 12, 2013
P4, N=43, Completed, Sponsor: Line Cleemann
Recruiting --> Completed N=60 --> 43